Skip to main content

Moderna, Inc. income statement

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026 · Market value $87.52B

Moderna, Inc. reported revenue of $1.94 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), down 39.9% from fiscal 2024. Net income was −$2.82 billion and diluted earnings per share −$7.26.

From Moderna, Inc.'s annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Moderna, Inc. income statement, annual
USDFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$108.4M$205.8M$135.1M$60.21M$803.0M$18.47B$19.26B$6.85B$3.24B$1.94B$2.52B
Revenue growth—+89.9%−34.4%−55.4%+1234%+2200%+4.3%−64.4%−52.7%−39.9%—
Cost of revenue——$0.00$0.00$8.00M$2.62B$5.42B$4.69B$1.46B$868.0M$1.82B
Gross profit——$135.1M$60.21M$795.0M$15.85B$13.85B$2.15B$1.77B$1.08B$707.0M
Gross margin——100%100%99.0%85.8%71.9%31.5%54.8%55.3%28.0%
Research and development$274.7M$410.5M$454.1M$496.0M$1.37B$1.99B$3.29B$4.84B$4.54B$3.13B$2.66B
Selling, general and administrative$57.45M$64.72M$94.25M$110.0M$188.0M$567.0M$1.13B$1.55B$1.17B$1.02B—
Operating expenses$332.2M$475.2M$548.3M$605.9M$1.56B$2.56B$4.43B$6.39B$5.72B$4.15B—
Operating income−$223.8M−$269.4M−$413.3M−$546.0M−$763.0M$13.30B$9.42B−$4.24B−$3.94B−$3.07B−$2.93B
Operating margin−206%−131%−306%—−95.0%72.0%48.9%−61.9%−122%−158%−116%
Income before tax−$215.2M−$256.0M−$384.4M−$514.7M−$744.0M$13.29B$9.57B−$3.94B−$3.61B−$2.77B−$2.73B
Income tax expense$1.04M−$80.00K$326.0K−$1.00M$3.00M$1.08B$1.21B$772.0M−$46.00M$54.00M$60.00M
Effective tax rate−0.5%0.0%−0.1%0.2%−0.4%8.2%12.7%−19.6%1.3%−2.0%−2.2%
Net income−$216.2M−$255.9M−$384.7M−$514.0M−$747.0M$12.20B$8.36B−$4.71B−$3.56B−$2.82B−$2.79B
Net margin−199%−124%−285%—−93.0%66.1%43.4%−68.8%−110%−145%−110%
Net income to common shareholders−$230.3M−$269.8M−$401.9M————————
EPS · diluted−$3.79−$4.18−$4.95−$1.55−$1.96$28.29$20.12−$12.33−$9.28−$7.26−$6.91
Diluted weighted average shares60.7M64.5M81.1M331M381M431M416M382M384M389M404M
Basic weighted average shares60.7M64.5M81.1M331M381M403M394M382M384M389M396M
EBITDA−$208.7M−$248.8M−$388.4M−$515.0M−$732.0M$13.53B$9.77B−$3.62B−$3.76B−$2.86B−$2.69B
EBITDA margin−192%−121%−288%—−91.2%73.2%50.7%−52.9%−116%−147%−107%
Depreciation & amortization$15.11M$20.54M$24.86M$31.00M$31.00M$232.0M$348.0M$617.0M$185.0M$211.0M$239.0M
Stock-based compensation$39.36M$40.05M$72.56M$81.00M$93.00M$142.0M$226.0M$305.0M$429.0M$483.0M$464.0M

Quarterly

Moderna, Inc. income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$2.81B$167.0M$241.0M$1.86B$966.0M$108.0M$142.0M$1.02B$678.0M$389.0M$145.0M$1.31B
Cost of revenue$929.0M$96.00M$115.0M$514.0M$739.0M$90.00M$119.0M$207.0M$452.0M$955.0M$93.00M$318.0M
Gross profit$1.88B$71.00M$126.0M$1.35B$227.0M$18.00M$23.00M$809.0M$226.0M−$566.0M$52.00M$995.0M
Gross margin67.0%42.5%52.3%72.4%23.5%16.7%16.2%79.6%33.3%−146%35.9%75.8%
Research and development$1.41B$1.06B$1.22B$1.14B$1.12B$856.0M$700.0M$801.0M$775.0M$649.0M$651.0M$583.0M
Selling, general and administrative$470.0M$274.0M$268.0M$281.0M$351.0M$212.0M$230.0M$268.0M$308.0M$173.0M$216.0M—
Operating expenses$1.88B$1.34B$1.49B$1.42B$1.47B$1.07B$930.0M$1.07B$1.08B$822.0M$867.0M—
Operating income$6.00M−$1.27B−$1.36B−$70.00M−$1.25B−$1.05B−$907.0M−$260.0M−$857.0M−$1.39B−$815.0M$130.0M
Operating margin0.2%——−3.8%−129%——−25.6%−126%−357%—9.9%
Income before tax$70.00M−$1.17B−$1.28B$21.00M−$1.18B−$964.0M−$818.0M−$187.0M−$799.0M−$1.33B−$767.0M$171.0M
Income tax expense−$147.0M$10.00M$0.00$8.00M−$64.00M$7.00M$7.00M$13.00M$27.00M$9.00M$15.00M$9.00M
Effective tax rate−210%−0.9%0.0%38.1%5.4%−0.7%−0.9%−7.0%−3.4%−0.7%−2.0%5.3%
Net income$217.0M−$1.18B−$1.28B$13.00M−$1.12B−$971.0M−$825.0M−$200.0M−$826.0M−$1.34B−$782.0M$162.0M
Net margin7.7%——0.7%−116%——−19.7%−122%−345%—12.3%
EPS · diluted$0.57−$3.07−$3.33$0.03−$2.90−$2.52−$2.13−$0.51−$2.11−$3.40−$1.97$0.38
Diluted weighted average shares382M382M384M399M386M386M388M390M392M395M398M430M
Basic weighted average shares382M382M384M385M387M386M388M390M392M395M398M401M
EBITDA$209.0M−$1.23B−$1.32B−$19.00M−$1.19B−$1.01B−$851.0M−$209.0M−$791.0M−$1.33B−$759.0M$191.0M
EBITDA margin7.4%——−1.0%−123%——−20.6%−117%−342%—14.5%
Depreciation & amortization$203.0M$35.00M$40.00M$51.00M$59.00M$38.00M$56.00M$51.00M$66.00M$56.00M$56.00M$61.00M
Stock-based compensation$79.00M$101.0M$112.0M$112.0M$104.0M$115.0M$130.0M$125.0M$113.0M$104.0M$120.0M$127.0M

The main figures as JSON and plain text. See data and methodology.

MRNA in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.